Streetbeat News

Price Targets

PXLW

Needham analyst Quinn Bolton has reiterated a 'Buy' rating on Pixelworks (NASDAQ:PXLW) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 8:24 am

ICE

Raymond James analyst Patrick O'Shaughnessy has maintained a 'Strong Buy' rating on Intercontinental Exchange (NYSE:ICE), but lowered the price target from $137 to $135.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 8:18 am

FVRR

UPWK

UBS analyst Kunal Madhukar initiated coverage on Fiverr International Ltd (FVRR) with a Buy rating and a price target of $33. Despite current market uncertainty, the analyst sees potential for growth in 2024. The analyst also compared Fiverr's valuation multiple to that of Upwork Inc (UPWK), which has historically traded at a discount to FVRR.

Portfolio Pulse from Shivani Kumaresan

October 04, 2023 | 8:24 pm

FLR

UBS analyst Steven Fisher upgraded Fluor Corporation (NYSE:FLR) to Buy from Neutral, raising the price target to $47 from $35. Fisher expects a 41% growth in adjusted EBITDA from 2023 to 2025, driven by a 160 bps expansion in segment margin. The analyst anticipates revenues to grow at a 9% CAGR for 2022-25 and segment margins to expand by 160bps. Fluor's adjusted EBITDA is forecasted to grow from $565 million in 2023 to $795 million in 2025.

Portfolio Pulse from Nabaparna Bhattacharya

October 04, 2023 | 8:23 pm

ET

A significant amount of unusual options activity has been detected for Energy Transfer (NYSE:ET), with a majority of investors taking a bearish stance. Of the 11 strange trades detected, 63% were bearish and 36% bullish. The total amount for the 7 puts was $298,325 and for the 4 calls was $146,980. Whales have been targeting a price range from $7.0 to $17.0 for Energy Transfer over the last 3 months. The current price of ET is down -0.37% at $13.5.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 8:16 pm

TAK

Takeda Pharmaceutical Inc. (NYSE:TAK) shares are currently trading at $14.63, after a 2.14% drop. Over the past month, the stock decreased by 3.56%, but over the past year, it increased by 11.51%. The company's P/E ratio is lower than the aggregate P/E of the Pharmaceuticals industry, indicating that the stock might be undervalued.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 8:00 pm

AA

Jefferies analyst Chris LaFemina maintains a Buy rating on Alcoa (NYSE:AA) but lowers the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 7:33 pm

BTU

Jefferies analyst Chris LaFemina maintains a Buy rating on Peabody Energy (NYSE:BTU) and raises the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 7:32 pm

HCC

Jefferies analyst Chris LaFemina maintains a Buy rating on Warrior Met Coal (NYSE:HCC) and raises the price target from $55 to $60.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 7:30 pm

METC

Jefferies analyst Chris LaFemina maintains a 'Buy' rating on Ramaco Resources (NASDAQ:METC) and raises the price target from $10.5 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 7:28 pm